Unlike orphan indications shielded by exclusion, Type 2 Diabetes is where IRA negotiation bites hardest — six high-volume agents across the first two cycles, resetting the class price anchor.
Type 2 Diabetes sits at the centre of the Inflation Reduction Act's Medicare Drug Price Negotiation Program, the opposite of an orphan market shielded by exclusion. In the first cycle (IPAY 2026, Maximum Fair Prices effective January 1, 2026), three T2D orals were negotiated: Januvia (sitagliptin, DPP-4) to $113 from a $527 list, Jardiance (empagliflozin, SGLT2) to $197 from $573, and Farxiga (dapagliflozin, SGLT2) to $178 from $556; the insulin NovoLog/Fiasp also appeared on the ten-drug list. The second cycle (IPAY 2027, effective January 1, 2027) extends negotiation to semaglutide (Ozempic, Rybelsus and Wegovy), cut 71% to $274 for a 30-day supply (higher-dose Wegovy at $385), alongside the DPP-4 agents Janumet (sitagliptin/metformin) and Tradjenta (linagliptin).
Carrying the competitive picture from the AXLRx CI brief: tirzepatide holds 41% of new GLP-1 starts and semaglutide's SELECT cardiovascular label drives formulary priority, but both now sit against negotiated SGLT2/DPP-4 anchors and, for semaglutide, its own 2027 MFP. On value, ICER's 2019 Type 2 Diabetes assessment evaluated oral semaglutide (Rybelsus) as add-on to metformin and found it met commonly cited cost-effectiveness thresholds but was less cost-effective than empagliflozin — an early signal of the SGLT2-versus-incretin value tension payers now navigate.
US Type 2 Diabetes agents — IRA negotiation status & Maximum Fair Prices
| Drug (Brand / INN) | Class | Benefit Routing | IRA Selection | Negotiated MFP (from list) | Access Implication |
|---|---|---|---|---|---|
| Januvia (sitagliptin) | DPP-4 inhibitor | Medicare Part D (oral) | IPAY 2026 — MFP effective Jan 1, 2026 | $113/mo from $527 list (~79%) | First DPP-4 price reset; anchors oral T2D net pricing |
| Jardiance (empagliflozin) | SGLT2 inhibitor | Medicare Part D (oral) | IPAY 2026 — MFP effective Jan 1, 2026 | $197/mo from $573 list (~66%) | SGLT2 anchor reset; narrows gap to GLP-1 net price |
| Farxiga (dapagliflozin) | SGLT2 inhibitor | Medicare Part D (oral) | IPAY 2026 — MFP effective Jan 1, 2026 | $178/mo from $556 list (~68%) | SGLT2 anchor reset; renal/HF label supports positioning |
| Ozempic / Rybelsus (semaglutide) | GLP-1 RA | Medicare Part D (SC / oral) | IPAY 2027 — MFP effective Jan 1, 2027 | $274/mo from ~$959 list (71%) | GLP-1 anchor cut; Wegovy higher dose at $385/mo |
| Janumet (sitagliptin/metformin) | DPP-4 combination | Medicare Part D (oral) | IPAY 2027 — MFP effective Jan 1, 2027 | Negotiated; MFP effective 2027 | Extends DPP-4 reset to fixed-dose combination |
| Tradjenta (linagliptin) | DPP-4 inhibitor | Medicare Part D (oral) | IPAY 2027 — MFP effective Jan 1, 2027 | Negotiated; MFP effective 2027 | Broadens DPP-4 class negotiation exposure |
Sources: CMS Medicare Drug Price Negotiation Program — negotiated prices for IPAY 2026 (effective Jan 1, 2026) and selected-drug list for IPAY 2027 (effective Jan 1, 2027); ICER Diabetes: Type 2 Evidence Report (2019); list prices per CMS negotiation announcements.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Selected-drug mapping across IPAY 2026 (Januvia, Jardiance, Farxiga) and IPAY 2027 (semaglutide, Janumet, Tradjenta)
- negotiated MFP vs list price by agent
- effective dates and Part D scope
Delivers
- Net-price parity analysis as MFPs take effect
- rebate-economics shift on the SGLT2/DPP-4 anchor
- whether narrowing price gaps ease or harden GLP-1 prior-auth and step-edit barriers
Delivers
- Current formulary tier and PA criteria at major commercial payers and Part D plans
- CV/renal-indication coverage triggers
- GLP-1 supply and coverage constraints affecting access
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How Type 2 Diabetes sits at the center of the IRA's Medicare Drug Price Negotiation Program rather than being shielded from it
- Why six T2D agents across DPP-4, SGLT2, and GLP-1 classes have now been negotiated across the first two IRA cycles
- IPAY 2026's three negotiated orals: Januvia to $113 from $527, Jardiance to $197 from $573, and Farxiga to $178 from $556
- IPAY 2027's extension to semaglutide (cut 71% to $274/month) plus Janumet and Tradjenta, effective January 1, 2027
- How negotiation at the active-ingredient level makes the $274 semaglutide MFP apply across Ozempic, Rybelsus, and Wegovy
- Why narrowing the SGLT2/DPP-4 net-price gap to GLP-1 agents changes rebate economics and step-edit logic through 2028
- ICER's 2019 Type 2 Diabetes assessment, which found oral semaglutide (Rybelsus) cost-effective but less so than empagliflozin
- Why this SGLT2-versus-incretin value tension continues to shape payer formulary and step-edit design
- Current formulary tier and PA criteria at major commercial payers and Part D plans for GLP-1 agents
- How CV- and renal-indication coverage triggers and supply constraints shape GLP-1 access
- How tirzepatide's 41% share of new GLP-1 starts and semaglutide's SELECT cardiovascular label interact with negotiated SGLT2/DPP-4 anchors
- The net-pricing trajectory as six T2D agents carry Maximum Fair Prices into 2028
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
US Type 2 Diabetes P&HTA is built from CMS Medicare Drug Price Negotiation Program documentation, ICER evidence reports, Medicare Part D benefit specifications, and live payer formulary and PA policy documents from major commercial and Part D plans. No secondary summaries or unverified estimates are used; every figure is verified against its primary source.
Key sources: CMS Medicare Drug Price Negotiation Program — IPAY 2026 negotiated-price fact sheet and IPAY 2027 selected-drug list and negotiated prices; ICER Diabetes: Type 2 Evidence Report (2019, oral semaglutide add-on assessment); CMS Part D benefit design; major payer PA clinical coverage policies (current versions).
- IPAY 2026 selected agents and Maximum Fair Prices (Januvia $113, Jardiance $197, Farxiga $178) verified against the CMS IPAY 2026 negotiated-price fact sheet
- IPAY 2027 selection of semaglutide ($274/mo, 71% cut; Wegovy $385), Janumet, and Tradjenta verified against the CMS IPAY 2027 selected-drug list and negotiated prices
- ICER value positioning (oral semaglutide met cost-effectiveness thresholds but less than empagliflozin) verified against the ICER Diabetes: Type 2 Evidence Report (2019)
- Benefit routing (Part D) and PA/step-edit criteria verified against CMS classification and current commercial payer coverage policy documents
Frequently asked questions
Commission this assessment
AXLRx US Type 2 Diabetes Payer & HTA is built for market access, HEOR, and pricing teams navigating IRA negotiation across the SGLT2, DPP-4, and GLP-1 classes and the resulting Part D formulary reset. Custom assessment in 72 hours.
Specify indication, payer focus (IRA negotiation, MFP impact, ICER, PA criteria), and commercial question.
AXLRx analyst confirms payer scope, IRA cycle analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.